{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loteprednol+Etabonate",
    "query": {
      "intervention": "Loteprednol Etabonate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loteprednol+Etabonate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T03:42:25.669Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01193504",
      "title": "Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pseudophakia",
        "Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "Pred Forte",
          "type": "DRUG"
        },
        {
          "name": "Lotemax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2010-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-06-14",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 3,
      "location_summary": "Laguna Hills, California • Miami, Florida • Waltham, Massachusetts",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193504"
    },
    {
      "nct_id": "NCT02813265",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 918,
      "start_date": "2016-06",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 60,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02813265"
    },
    {
      "nct_id": "NCT03063489",
      "title": "Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Pain"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-02",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03063489"
    },
    {
      "nct_id": "NCT00407043",
      "title": "Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Disease",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Lotemax",
          "type": "DRUG"
        },
        {
          "name": "Restasis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthalmic Consultants of Long Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2006-11",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2011-07-21",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 1,
      "location_summary": "Lynbrook, New York",
      "locations": [
        {
          "city": "Lynbrook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407043"
    },
    {
      "nct_id": "NCT02218489",
      "title": "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "KPI-121",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-07",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218489"
    },
    {
      "nct_id": "NCT01443442",
      "title": "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "bepotastine besilate, 1.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California College of Optometry at Marshall B. Ketchum University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 2,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443442"
    },
    {
      "nct_id": "NCT02819284",
      "title": "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of KPI-121 0.25% Ophthalmic Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kala Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 909,
      "start_date": "2016-06",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819284"
    },
    {
      "nct_id": "NCT05542381",
      "title": "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel [Lotemax]",
          "type": "DRUG"
        },
        {
          "name": "Refresh Lubricant Eye Drops [Artificial Tears]",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-12-22",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05542381"
    },
    {
      "nct_id": "NCT01736527",
      "title": "Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "LE Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-01",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2013-11-08",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736527"
    },
    {
      "nct_id": "NCT05136443",
      "title": "Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Corneal Endothelial Dystrophy",
        "Corneal Edema"
      ],
      "interventions": [
        {
          "name": "loteprednol etabonate 0.25% ophthalmic suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Price Vision Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-11-23",
      "completion_date": "2023-09-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-09-23T03:42:25.669Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136443"
    }
  ]
}